Sonoma Pharmaceuticals (SNOA) Shares Outstanding (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Shares Outstanding (Entity) of $1.8 million for Q1 2026, up 44.97% year-over-year from $1.2 million in Q1 2025, and up 3.95% quarter-over-quarter from $1.7 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Shares Outstanding (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 44.97% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 44.97% YoY), while the FY2026 annual figure was $1.8 million, up 44.97% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $1.8 million, up from $1.7 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $1.8 million in Q1 2026, with the low at $155.0 in Q3 2022.
- The 5-year median for Shares Outstanding (Entity) is $545450.0 (2023), against an average of $763189.1.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) tumbled 99.89% in 2023, then jumped 400675.19% in 2024.
- Sonoma Pharmaceuticals' Shares Outstanding (Entity) stood at $155.0 in 2022, then surged by 351803.23% to $545450.0 in 2023, then surged by 196.23% to $1.6 million in 2024, then advanced by 7.11% to $1.7 million in 2025, then increased by 3.95% to $1.8 million in 2026.
- Business Quant data shows SNOA's Shares Outstanding (Entity) at $1.8 million in Q1 2026, $1.7 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 832.44 Mn |
| 10 | Sonoma Pharmaceuticals | 5.15 Mn | -184,359.87 | 2.58 Mn | 3.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.85 Mn |
| Mar 31, 2026 | 1.68 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 851,450.00 |
| Mar 31, 2024 | 454,500.00 |
| Dec 31, 2023 | 545,450.00 |
| Sep 30, 2023 | 258.00 |
| Jun 30, 2023 | 247.00 |
| Mar 31, 2023 | 170.00 |
| Dec 31, 2022 | 155.00 |
| Sep 30, 2022 | 155.00 |
| Jun 30, 2022 | 155,050.00 |
| Mar 31, 2022 | 132,650.00 |
| Dec 31, 2021 | 154.00 |
| Sep 30, 2021 | 117,200.00 |